☆ 4.7 Letter

Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

ANNALS OF THE RHEUMATIC DISEASES (2021)

Get Full Text
Add to Collection

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 80, Issue 7, Pages 954-955

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2020-219803

Keywords

lupus erythematosus; systemic; cytokines; biological therapy

Categories

Rheumatology

Funding

  1. Immunomedics, Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.